Limits...
Predictive cytogenetic biomarkers for colorectal neoplasia in medium risk patients.

Ionescu EM, Nicolaie T, Ionescu MA, Becheanu G, Andrei F, Diculescu M, Ciocirlan M - J Med Life (2015 Jul-Sep)

Bottom Line: MN frequency and NPB presence were not significantly different in patients with neoplastic lesions compared to controls.NDI score may have a role as a colorectal cancer-screening test in "medium risk" individuals.DNA = deoxyribonucleic acid; CRC = colorectal cancer; EU = European Union; WHO = World Health Organization; FOBT = fecal occult blood test; CBMN = cytokinesis-blocked micronucleus assay; MN = micronuclei; NPB = nucleoplasmic bridges; NDI = Nuclear Division Index; FAP = familial adenomatous polyposis; HNPCC = hereditary non-polypoid colorectal cancer; IBD = inflammatory bowel diseases; ROC = receiver operating characteristics; AUROC = area under the receiver operating characteristics curve.

View Article: PubMed Central - PubMed

Affiliation: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

ABSTRACT

Rationale: DNA damage and chromosomal alterations in peripheral lymphocytes parallels DNA mutations in tumor tissues.

Objective: The aim of our study was to predict the presence of neoplastic colorectal lesions by specific biomarkers in "medium risk" individuals (age 50 to 75, with no personal or family of any colorectal neoplasia).

Methods and results: We designed a prospective cohort observational study including patients undergoing diagnostic or opportunistic screening colonoscopy. Specific biomarkers were analyzed for each patient in peripheral lymphocytes - presence of micronuclei (MN), nucleoplasmic bridges (NPB) and the Nuclear Division Index (NDI) by the cytokinesis-blocked micronucleus assay (CBMN). Of 98 patients included, 57 were "medium risk" individuals. MN frequency and NPB presence were not significantly different in patients with neoplastic lesions compared to controls. In "medium risk" individuals, mean NDI was significantly lower for patients with any neoplastic lesions (adenomas and adenocarcinomas, AUROC 0.668, p 00.5), for patients with advanced neoplasia (advanced adenoma and adenocarcinoma, AUROC 0.636 p 0.029) as well as for patients with adenocarcinoma (AUROC 0.650, p 0.048), for each comparison with the rest of the population. For a cut-off of 1.8, in "medium risk" individuals, an NDI inferior to that value may predict any neoplastic lesion with a sensitivity of 97.7%, an advanced neoplastic lesion with a sensitivity of 97% and adenocarcinoma with a sensitivity of 94.4%.

Discussion: NDI score may have a role as a colorectal cancer-screening test in "medium risk" individuals.

Abbreviations: DNA = deoxyribonucleic acid; CRC = colorectal cancer; EU = European Union; WHO = World Health Organization; FOBT = fecal occult blood test; CBMN = cytokinesis-blocked micronucleus assay; MN = micronuclei; NPB = nucleoplasmic bridges; NDI = Nuclear Division Index; FAP = familial adenomatous polyposis; HNPCC = hereditary non-polypoid colorectal cancer; IBD = inflammatory bowel diseases; ROC = receiver operating characteristics; AUROC = area under the receiver operating characteristics curve.

No MeSH data available.


Related in: MedlinePlus

AUC ROC of NDI to predict colorectal advanced neoplasia (advanced adenoma and cancer) for “medium risk group” individuals
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556926&req=5

Figure 2: AUC ROC of NDI to predict colorectal advanced neoplasia (advanced adenoma and cancer) for “medium risk group” individuals

Mentions: The predictive value of NDI in colorectal neoplastic lesions - any neoplasia, advanced neoplasia and adenocarcinoma


Predictive cytogenetic biomarkers for colorectal neoplasia in medium risk patients.

Ionescu EM, Nicolaie T, Ionescu MA, Becheanu G, Andrei F, Diculescu M, Ciocirlan M - J Med Life (2015 Jul-Sep)

AUC ROC of NDI to predict colorectal advanced neoplasia (advanced adenoma and cancer) for “medium risk group” individuals
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556926&req=5

Figure 2: AUC ROC of NDI to predict colorectal advanced neoplasia (advanced adenoma and cancer) for “medium risk group” individuals
Mentions: The predictive value of NDI in colorectal neoplastic lesions - any neoplasia, advanced neoplasia and adenocarcinoma

Bottom Line: MN frequency and NPB presence were not significantly different in patients with neoplastic lesions compared to controls.NDI score may have a role as a colorectal cancer-screening test in "medium risk" individuals.DNA = deoxyribonucleic acid; CRC = colorectal cancer; EU = European Union; WHO = World Health Organization; FOBT = fecal occult blood test; CBMN = cytokinesis-blocked micronucleus assay; MN = micronuclei; NPB = nucleoplasmic bridges; NDI = Nuclear Division Index; FAP = familial adenomatous polyposis; HNPCC = hereditary non-polypoid colorectal cancer; IBD = inflammatory bowel diseases; ROC = receiver operating characteristics; AUROC = area under the receiver operating characteristics curve.

View Article: PubMed Central - PubMed

Affiliation: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

ABSTRACT

Rationale: DNA damage and chromosomal alterations in peripheral lymphocytes parallels DNA mutations in tumor tissues.

Objective: The aim of our study was to predict the presence of neoplastic colorectal lesions by specific biomarkers in "medium risk" individuals (age 50 to 75, with no personal or family of any colorectal neoplasia).

Methods and results: We designed a prospective cohort observational study including patients undergoing diagnostic or opportunistic screening colonoscopy. Specific biomarkers were analyzed for each patient in peripheral lymphocytes - presence of micronuclei (MN), nucleoplasmic bridges (NPB) and the Nuclear Division Index (NDI) by the cytokinesis-blocked micronucleus assay (CBMN). Of 98 patients included, 57 were "medium risk" individuals. MN frequency and NPB presence were not significantly different in patients with neoplastic lesions compared to controls. In "medium risk" individuals, mean NDI was significantly lower for patients with any neoplastic lesions (adenomas and adenocarcinomas, AUROC 0.668, p 00.5), for patients with advanced neoplasia (advanced adenoma and adenocarcinoma, AUROC 0.636 p 0.029) as well as for patients with adenocarcinoma (AUROC 0.650, p 0.048), for each comparison with the rest of the population. For a cut-off of 1.8, in "medium risk" individuals, an NDI inferior to that value may predict any neoplastic lesion with a sensitivity of 97.7%, an advanced neoplastic lesion with a sensitivity of 97% and adenocarcinoma with a sensitivity of 94.4%.

Discussion: NDI score may have a role as a colorectal cancer-screening test in "medium risk" individuals.

Abbreviations: DNA = deoxyribonucleic acid; CRC = colorectal cancer; EU = European Union; WHO = World Health Organization; FOBT = fecal occult blood test; CBMN = cytokinesis-blocked micronucleus assay; MN = micronuclei; NPB = nucleoplasmic bridges; NDI = Nuclear Division Index; FAP = familial adenomatous polyposis; HNPCC = hereditary non-polypoid colorectal cancer; IBD = inflammatory bowel diseases; ROC = receiver operating characteristics; AUROC = area under the receiver operating characteristics curve.

No MeSH data available.


Related in: MedlinePlus